John E. Trusheim
Impact in
- Genetics top 1%
- Glioma Diagnosis and Treatment
- Immunology top 5%
- Immunotherapy and Immune Responses
- Immune cells in cancer
Papers in
- Co-authors
- Jennifer Connelly (1 shared paper)Erin M Dunbar (1 shared paper)James D. Battiste (1 shared paper)Denise Damek (1 shared paper)Nimish A. Mohile (1 shared paper)Daniela Annenelie Bota (1 shared paper)FABIO MASSAITI IWAMOTO (1 shared paper)Michael SW Lee (1 shared paper)
- Journals
- Neuro-Oncology (3 papers)The Lancet Oncology (1 paper)JAMA Oncology (1 paper)Journal of Translational Medicine (1 paper)CNS Oncology (1 paper)
- Partner nations
- United StatesIndiaNetherlands
In The Last Decade
John E. Trusheim
8 papers receiving 1.8k citations
John E. Trusheim's Hit Papers
Peers
Comparison fields: 5 of 76
- Genetics 992
- Immunology 720
- Oncology 679
- Cancer Research 198
- Neurology 57
Countries citing papers authored by John E. Trusheim
This map shows the geographic impact of John E. Trusheim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Trusheim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Trusheim more than expected).
Fields of papers citing papers by John E. Trusheim
This network shows the impact of papers produced by John E. Trusheim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Trusheim. The network helps show where John E. Trusheim may publish in the future.
Co-authors
The 9 scholars most cited alongside John E. Trusheim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Hit paper breakdown → | 2017 | 930 |
| 2 | First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma Hit paper breakdown → | 2018 | 457 |
| 3 | Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma Hit paper breakdown → | 2022 | 329 |
| 4 | 2016 | 39 | |
| 5 | 2010 | 17 | |
| 6 | 2018 | 8 | |
| 7 | 2013 | 3 | |
| 8 | 2012 | 1 |
About John E. Trusheim
John E. Trusheim is a scholar working on Genetics, Oncology, Ophthalmology, Neurology and Radiology, Nuclear Medicine and Imaging, having authored 8 papers that have together received 1.8k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (4 papers), Cancer Treatment and Pharmacology (2 papers), Drug-Induced Ocular Toxicity (1 paper), Neuroblastoma Research and Treatments (1 paper), Radiomics and Machine Learning in Medical Imaging (1 paper) and Pancreatic and Hepatic Oncology Research (1 paper). The work is most often cited by research in Genetics (992 citations), Immunology (720 citations), Oncology (679 citations), Cancer Research (198 citations) and Neurology (57 citations). John E. Trusheim has collaborated with scholars based in United States, India and Netherlands. Frequent co-authors include Jennifer Connelly, Erin M Dunbar, James D. Battiste, Denise Damek, Nimish A. Mohile, Daniela Annenelie Bota, FABIO MASSAITI IWAMOTO, Michael SW Lee and Collin M. McClelland. Their work appears in journals such as Neuro-Oncology, The Lancet Oncology, JAMA Oncology, Journal of Translational Medicine and CNS Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.